Terms ending in 2030
Every in-force patent on Aventis Pharma S.A.'s record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,481,589 | Novel Taxoid-Based Compositions In force · High confidence | Aventis Pharma S.A. | In force | High confidence | |
| US 8,927,592 | Novel Antitumoral Use of Cabazitaxel In force · Medium confidence | Sanofi Mature IP | In force | Medium confidence | |
| US 10,583,110 | Novel Antitumoral Use of Cabazitaxel In force · High confidence | Sanofi Mature IP | In force | High confidence | |
| US 10,716,777 | Novel Antitumoral Use of Cabazitaxel In force · Medium confidence | Sanofi Mature IP | In force | Medium confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Aventis Pharma S.A..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.